Authors

Latest:

Immunotherapy Paves Path for New Standards of Care in Gastroesophageal Cancers

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

Jonathan A. Chatzkel, MD

Latest:

Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold Tumors

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

Alain Charles Borczuk, MD

Latest:

Dr Borczuk on Currently Offered Gene Testing for Patients With Lung Cancer

Alain Charles Borczuk, MD, discusses gene testing that may be offered for patients with lung cancer.

Curtis Lachowiez, MD

Latest:

Best Practices for Virtual Conference Presentations

As the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.

Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center

Latest:

Using Systemic Therapy to Treat HER2+ Breast Cancer

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Markus Y. Mapara, MD, PhD

Latest:

Allogeneic Transplant and Gene Therapy in Sickle Cell Disease

Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.

Vishal A. Patel, MD, FAAD, FACMS

Vishal A. Patel, MD, is an associate professor of dermatology at the George Washington University School of Medicine & Health Sciences and director of the Cutaneous Oncology Program at the George Washington Cancer Center.

Latest:

Selecting Candidates for Adjuvant Immunotherapy in cSCC

Panelists discuss how clinicians identify which patients are most likely to benefit from adjuvant immunotherapy based on clinical and pathologic risk factors.

Jon O. Ebbert, MD, Mayo Clinic

Latest:

Future of Multi-Cancer Early Detection: A Recap and Horizon

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

Ana Christina Garrido-Castro, MD

Latest:

Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Burton Eliot Appel, MD

Latest:

Dr Appel on the Significance of International Childhood Cancer Day

Burton Eliot Appel, MD, discusses the significance of International Childhood Cancer Day.

John Chan, MD

John Chan, MD, is a volunteer clinical professor of obstetrics/gynecology, Reproductive Sciences, in the UCSF School of Medicine, as well as director of Gynecologic Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center.

Latest:

Ongoing Research to Watch in Advanced Endometrial Cancer in 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss ongoing research to watch in endometrial cancer.

Jessica Lin, MD

Latest:

Dr Lin on the Efficacy and Safety of Taletrectinib in ROS1 Fusion+ NSCLC

Jessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive NSCLC.

Antonia Sepulveda, MD, PhD

Latest:

Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

Justin M. Watts, MD

Latest:

Dr Watts on the Potential Advantages of INCB057643 in Advanced Myelofibrosis

Justin M. Watts, MD, discusses the potential advantages of the oral small molecule BET inhibitor INCB057643 in advanced myelofibrosis.

Rajiv Agarwal, MD, and Cathy Eng, MD

Latest:

Palliative Care for Young Adults Is a Growing Reality in CRC

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

Lorenzo Falchi, MD

Lorenzo Falchi, MD, is an assistant attending physician at Memorial Sloan Kettering Cancer Center.

Latest:

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Louise Catherine Connell, MB BCh BAO, BMedSc

Latest:

Case Studies with Hepatic Artery Infusion

Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, review cases of patients with colorectal cancer and provide insights on clinical practice.

Anna Lee, MD, MPH

Latest:

Dr Lee on Head and Neck Cancer Updates from the 2024 ACRO Summit

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

Carmen Criscitiello, MD, PhD

Latest:

Addressing Treatment Gaps in HER2+ MBC

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Rene Y. McNall-Knapp, MD

Rene Y. McNall-Knapp, MD, is a pediatric hematologist-oncologist at Jimmy Everest Center at Oklahoma Children’s Hospital OU Health and professor in the Department of Pediatrics at the University of Oklahoma Health Sciences Center.

Latest:

Dr McNall-Knapp on the Efficacy of MEK Inhibition in NF1-Associated PNs

Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.